| Budget Amount *help |
¥2,500,000 (Direct Cost: ¥2,500,000)
Fiscal Year 1998: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1997: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Research Abstract |
1). We investigated the lung injury of the mice in the treatment of the combination of chemotherapy such as irinotecan and cisplatin and radiotherapy. Mice were irradiated to hemithoraxs and the dose range was 5 Gy to 15 Gy. Mice was sacrificed weekly and then monthly until 3 months after treatment. The histology of the both lung, one was irradiated and the other was not irradiated, was studied using HE stain. We could not find significant histological change in the irradiated lung. We also measured the mRNA of TGFb in the lung, however the results were not obtained.
2). We evaluated the risk factors associated with development of neumonitis following chemoradiotherapy (CRT). Sixty patients were examined retrospectively. The irradiated area more than 200 cm2, lower lung field and concurrent use of irinotecan were identified the risk factors of pneumonitis. (European J Cancer 34, 71-75, 1998)
3). Bronchio-alveolar lavage fluid (BALF) and serum in the patients who were received CRT were ex
… More
amined before and after treatment. Lymphocytes, neutrophils and albumen in the BALF were significantly increased in not irradiated site lung. These results was suggested that the not irradiated lung was influenced in the treatment of CRT.(The J of Japanese Respiratory Society 37, 276, 1999)
4). We conducted the phase I study of concurrent use of irinotecan and radiation in the 26 patients with locally advanced non-small cell lung cancer (NSCLC). The dose limiting toxicity (DLT) were pneumonitis, esophagitis and diarrhea. The maximum tolerated dose (MTD) of irinotecan was 60 mg/m2 and recommended dose was 45 mg/m2. The response rate and median survival time (MST)were 75 % and 15.6 months. (British I Cancer, in press, 1999)
5). Next our combined modality using irinotecan was the combination of irinotecan, carboplatin and radiation. We performed the phase I study of this combination in the 31 patients with stage III NSCLC.The DLT were uneumonitis, neutropenia and thrombocytepenia. The MTD was 60 mg/m2 of CPT-11 and recommended dose of phase II study was 5O mg/m2. The response rate, . MST, 1 year and 2 year-survival were 60%, 18.8 months, 56.2% and 30.7%, respectively. This treatment is promising combined modality in the patients with unresectable stage III NSCLC.(Proc Am Soc Clin Oncol 17, in press, 1999) Less
|
